Login to Your Account



EIB investing $102M in UCB R&D pipeline in risk-sharing model

By Nuala Moran
Staff Writer

Tuesday, June 17, 2014

LONDON – The European Investment Bank (EIB) is to put in €75 million (US$101.8 million) to directly fund six research programs at pharma company UCB SA, as part of a new "at-risk co-development funding" instrument under which the bank will invest €24 billion in R&D projects over the next seven years.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription